Funder
National Institutes of Health
National Cancer Institute Division of Cancer Prevention
Ragon Institute of MGH, MIT and Harvard
Massachusetts Consortium on Pathogen Readiness
Reference8 articles.
1. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86;Lasrado;Vaccine,2023
2. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination;Stankov;Lancet Infect Dis,2024
3. Marking U, Bladh O, Aguilera K, et al. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden. The Lancet Infectious Diseases.
4. Wang Q, Guo Y, Bowen A, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host & Microbe.
5. Link-Gelles R CA, Mak J, et al. Early estimates of updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating omicron variants among immunocompetent adults — increasing community access to testing program, United States, September 2023–January 2024. MMWR Morb Mortal Wkly Rep 2024;73:77–83.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献